Calliditas Therapeutics Reports Data From Phase 2 Study Of Setanaxib In Combination With Pembrolizumab For Head And Neck Cancer
Calliditas Therapeutics Reports Data From Phase 2 Study Of Setanaxib In Combination With Pembrolizumab For Head And Neck Cancer
Calliditas Therapeutics AB (NASDAQ:CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck (SCCHN). The analysis showed statistically significant improvements in progression-free survival (PFS), as well as in overall survival (OS), with statistically significant changes in tumor biology consistent with the mechanism of action of setanaxib.
Calliditas Therapeutics AB（纳斯达克股票代码：CALT）（纳斯达克斯德哥尔摩股票代码：CALTX）（“Calliditas”）今天公布了其主要氮氧化物酶抑制剂setanaxib与pembrolizumab联合治疗头颈部鳞状细胞癌（SCCHN）患者的概念验证2期试验的数据。分析显示，无进展存活率（PFS）和总存活率（OS）具有统计学上的显著改善，肿瘤生物学的统计学显著变化与setanaxib的作用机制一致。